Overview

The Real Life Topical Field Treatment of Actinic Keratosis Study

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:
0

Participant gender:
All

Summary

This non-interventional, multinational study of topical field treatment of actinic keratosis (AK) aims to collect real-life experience with ingenol mebutate as well as one or two other topical field therapies commonly used in the individual country. Physicians will report baseline characteristics, while the main study focus will be on patient reported outcomes 3-4 weeks after treatment completion (treatment satisfaction, adherence, resource utilization and Health Related Quality of Life. Dermatology centres in Denmark, Norway, Sweden, the Netherlands, the United Kingdom and Canada will participate.

Accepts Healthy Volunteers?

Details

Lead Sponsor:

LEO Pharma

Treatments:

Diclofenac
Fluorouracil
Imiquimod

Criteria

Inclusion Criteria: Patients eligible to receive topical treatment with one of the
following for treatment of actinic keratosis at the discretion of the dermatologist:
Ingenol mebutate, 5-fluorouracil, imiquimod, diclofenac. Informed consent.

-

Exclusion Criteria: Any on-going treatments at study start with ingenol mebutate,
5-fluorouracil, imiquimod or diclofenac; other topical treatment for AK in treatment area;
pregnancy or planned pregnancy within treatment period.

-